Accessibility Information

Users of assistive technologies such as screen readers should use the following link to activate Accessibility Mode before continuing: Learn more and Activate accessibility mode.

68 -- recombinant Protective Antigen (rPA) anthrax vaccine for the strategic national stockpile

Solicitation Number: RFP-BARDA-08-15
Agency: Department of Health and Human Services
Office: Office of the Secretary
Location: Acquisitions Management, Contracts, & Grants (AMCG)
  • Print

Note:

There have been modifications to this notice. To view the most recent modification/amendment, click here
:
RFP-BARDA-08-15
:
Solicitation
:
Added: February 12, 2008 Modified: May 09, 2008 2:22 pmTrack Changes
The United States Government (USG) has a need to acquire and supply the Strategic National Stockpile (SNS) with 25 million doses of Final Drug Product (FDP) of recombinant protective antigen (rPA) anthrax vaccine. The FDP shall be packaged as single dose units or multi-dose vials with a minimum expiry period of 24 months manufactured in accordance with current Good Manufacturing Practice (cGMP). The rPA anthrax vaccine will initially be accepted into the SNS once the successful Offeror has supplied sufficient safety, efficacy, and stability data to support FDA (Food & Drug Administration)/CBER (Center for Biologics Evaluation & Research) Current Thinking for the potential use under a declared emergency under Emergency Use Authorization (EUA) for a post exposure prophylaxis indication (PEP), concurrent with antibiotics indication. The successful Offeror will be required to seek and achieve licensure for their rPA anthrax vaccine. Initial licensed product will be used in a pre-exposure general use prophylaxis (GUP) indication in adults. The Contractor shall also seek label extension for PEP plus antibiotic indication in adults in the base contract.

The Government intends to have a full & open competition for this requirement in the form of a Request For Proposal (RFP). This synopsis is not a RFP; an RFP is anticipated on February 29, 2008, with proposal submission in May 29, 2008. The Government expects to make 1 or more awards, subject to the availability of funds, on or about September 26, 2008.



Comments to this announcement, referencing synopsis RFP-BARDA-08-15 may be submitted to Brian K. Goodger, Contracting Officer at 202-260-0333 or in writing to Brian.Goodger@hhs.gov



This proposed acquisition is subject to the availability of Project BioShield Funds.

Added: Dec 07, 2009 6:39 pm
Amendment 5 - No award(s) will be made, this soliciation is cancelled.
Please consult the list of document viewers if you cannot open a file.

Solicitation 1

Type:
Solicitation
Posted Date:
February 28, 2008
Description: RFP attachments BARDA-08-15
Description: RFP Face Page BARDA-08-15
Description: RFP pages 2-57 BARDA-08-15

Amendment 1

Type:
Mod/Amendment
Posted Date:
March 11, 2008
Description: Amendment 1

Amendment 2

Type:
Mod/Amendment
Posted Date:
March 27, 2008
Description: Amendment 02

Amendment 3

Type:
Mod/Amendment
Posted Date:
May 9, 2008
Description: Amendment 03

Amendment 4

Type:
Mod/Amendment
Posted Date:
June 30, 2008
Description: Amendment 04
:
Department of Health and Human Services, Office of the Secretary, Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority 330 Independence Avenue, SW, Rm G640, Washington, DC, 20201, UNITED STATES
:
TBD
00000
:
Brian K Goodger
Phone: 202-260-0333